Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: Pooled analysis of randomized controlled trials

Advances in Therapy

Volumn 31, Issue 6, 2014, Pages 604-620

  Etropolski, Mila ^a   Kuperwasser, Brigitte ^a   Flügel, Maren ^b   Häufel, Thomas ^b   Lange, Bernd ^b   Rauschkolb, Christine ^a   Laschewski, Frank ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

Adverse events; Chronic pain; Low back pain; Osteoarthritis pain; Oxycodone controlled release; Safety; Tapentadol extended release; Tolerability

Indexed keywords

OXYCODONE; PLACEBO; TAPENTADOL; ANALGESIC AGENT; DELAYED RELEASE FORMULATION; MU OPIATE RECEPTOR; PHENOL DERIVATIVE;

ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED DRUG RELEASE; DIARRHEA; DIZZINESS; DROWSINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIP OSTEOARTHRITIS; HIP PAIN; HUMAN; HYPERHIDROSIS; INSOMNIA; KNEE OSTEOARTHRITIS; KNEE PAIN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; OSTEOARTHRITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMNOLENCE; VOMITING; XEROSTOMIA; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; AGONISTS; ANALGESIA; CHRONIC PAIN; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; META ANALYSIS; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; ANALGESICS; CHRONIC PAIN; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LOW BACK PAIN; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; OXYCODONE; PAIN MANAGEMENT; PAIN MEASUREMENT; PHENOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, OPIOID, MU; TREATMENT OUTCOME;

EID: 84905380659     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0128-6     Document Type: Article

References (32)

1. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an internet-based survey. J Pain. 2010;11:1230-9.
2. Reid KJ, Harker J, Bala MM, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin. 2011;27:449-62.
3. Katz WA, Barkin RL. Dilemmas in chronic/persistent pain management. Am J Ther. 2008;15:256-64.
4. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287-333.
5. Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthr Cartil. 2007;15:957-65.
6. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174:1589-94.
7. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372-80.
8. Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10:147-59.
9. Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146:116-27.
10. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008;11:S5-62.
11. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231-56.
12. Christo PJ. Opioid effectiveness and side effects in chronic pain. Anesthesiol Clin N Am. 2003;21:699-713.
13. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7:R1046-51.
14. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician. 2008;11:S181-200.
15. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11:S105-20.
16. Tzschentke TM, Christoph T, Kögel B, et al. (-)-(1R,2R)- 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel m-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323:265-76.
17. Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol hydrochloride. Analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitor. Drugs Future. 2006;31:1053-61.
18. Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010;27:381-99.
19. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010;30:489-505.
20. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother. 2010;11:1787-804.
21. Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010;10:416-27.
22. Buynak R, Shapiro DY, Okamoto A, et al. Erratum: efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother. 2010;11:2773.
23. Slappendel R, Simpson K, Dubois D, Keininger DL. Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain. 2006;10:209-17.
24. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35:253-9.
25. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13:293-308.
26. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol. 1999;26:862-9.
27. Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain. 1999;15:179-83.
28. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med. 2000;160:853-60.
29. Friedmann N, Klutzaritz V, Webster L. Long-term safety of Remoxy® (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain. Pain Med. 2011;12:755-60.
30. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74:1347-54.
31. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35-42.
32. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181-7.